Long term follow up of patients who received repeat dose rituximab as maintenance therapy for ANCA associated vasculitis (AAV)

2013 ◽  
Vol 42 (4) ◽  
pp. 775-776 ◽  
Author(s):  
R. Smith ◽  
F. Alberici ◽  
R. Jones ◽  
D. Jayne
Keyword(s):  
Maintenance Therapy ◽  
Repeat Dose ◽  
Anca Associated Vasculitis ◽  
Long Term Follow Up

scholarly journals Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis

Rheumatology ◽  
2014 ◽  
Vol 54 (7) ◽  
pp. 1153-1160 ◽  
Author(s):  
Federico Alberici ◽  
Rona M. Smith ◽  
Rachel B. Jones ◽  
Darren M. Roberts ◽  
Lisa C. Willcocks ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Repeat Dose ◽  
Anca Associated Vasculitis ◽  
Long Term Follow Up

scholarly journals Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data

Rheumatology ◽  
2017 ◽  
Vol 56 (11) ◽  
pp. 1894-1901 ◽  
Author(s):  
Anoek A E de Joode ◽  
Jan Stephan F Sanders ◽  
Xavier Puéchal ◽  
Loic P Guillevin ◽  
Thomas F Hiemstra ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Anca Associated Vasculitis ◽  
Long Term Follow Up

scholarly journals Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis

2014 ◽  
Vol 9 (9) ◽  
pp. 1571-1576 ◽  
Author(s):  
Michael Walsh ◽  
Mikkel Faurschou ◽  
Annelies Berden ◽  
Oliver Flossmann ◽  
Ingeborg Bajema ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Anca Associated Vasculitis ◽  
Long Term Follow Up

R‐MACLO‐IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma ‐ long term follow up results

2021 ◽  
Author(s):  
Juan Pablo Alderuccio ◽  
Eduardo E. Saul ◽  
Sunil G. Iyer ◽  
Isildinha M. Reis ◽  
Alvaro J. Alencar ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Long Term Follow Up

scholarly journals Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis

2015 ◽  
Vol 75 (3) ◽  
pp. 526-531 ◽  
Author(s):  
Farah Tamirou ◽  
David D'Cruz ◽  
Shirish Sangle ◽  
Philippe Remy ◽  
Carlos Vasconcelos ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Lupus Nephritis ◽  
Positive Predictive Value ◽  
Maintenance Therapy ◽  
Early Response ◽  
Renal Outcome ◽  
Proliferative Lupus Nephritis ◽  
Long Term Follow Up

ObjectiveTo report the 10-year follow-up of the MAINTAIN Nephritis Trial comparing azathioprine (AZA) and mycophenolate mofetil (MMF) as maintenance therapy of proliferative lupus nephritis, and to test different definitions of early response as predictors of long-term renal outcome.MethodsIn 2014, data on survival, kidney function, 24 h proteinuria, renal flares and other outcomes were collected for the 105 patients randomised between 2002 and 2006, except in 13 lost to follow-up.ResultsDeath (2 and 3 in the AZA and MMF groups, respectively) and end-stage renal disease (1 and 3, respectively) were rare events. Time to renal flare (22 and 19 flares in AZA and MMF groups, respectively) did not differ between AZA and MMF patients. Patients with good long-term renal outcome had a much more stringent early decrease of 24 h proteinuria compared with patients with poor outcome. The positive predictive value of a 24 h proteinuria <0.5 g/day at 3 months, 6 months and 12 months for a good long-term renal outcome was excellent (between 89% and 92%). Inclusion of renal function and urinalysis in the early response criteria did not impact the value of early proteinuria decrease as long-term prognostic marker.ConclusionsThe long-term follow-up data of the MAINTAIN Nephritis Trial do not indicate that MMF is superior to AZA as maintenance therapy in a Caucasian population suffering from proliferative lupus nephritis. Moreover, we confirm the excellent positive predictive value of an early proteinuria decrease for long-term renal outcome.Trial registration numberNCT00204022.

scholarly journals Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse

Sarcoma ◽  
2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Alessandra Longhi ◽  
Marilena Cesari ◽  
Massimo Serra ◽  
Erminia Mariani
Keyword(s):  
Maintenance Therapy ◽  
Randomized Study ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Viscum Album ◽  
Lymphocyte Subpopulation ◽  
Oral Etoposide ◽  
Long Term Follow Up

Background. In relapsed osteosarcoma, the 5-yr postrelapse disease-free survival (PRDFS) rate after the second relapse is <20%. In June 2007, a randomized study was started comparing oral etoposide vs Viscum album fermentatum Pini (an extract derived from the parasitic plant Viscum album L., European mistletoe) as maintenance therapy in patients with metastatic osteosarcoma in complete surgical remission after the second relapse. The primary endpoint was the PRDFS rate at 12 months (compared to the historical control rate). This is a long-term updated result. Patients and Methods. 10 patients received oral etoposide 50 mg/m2 daily for 21 days every 28 days for 6 months, and 9 patients received Viscum album fermentatum Pini 3 times/wk subcutaneously for 1 year. The study closed early in July 2011 due to insufficient recruitment. Lymphocyte subpopulations were analyzed at T0, T3, T6, T9, and T12 months. Results. On 30 June 2019, at a median follow-up ITT of 83 months (range 3–144 ms), a median PRDFS of 106 ms (2–144) was observed in the Viscum arm with 5/9 patients who never relapse vs a PRDFS of 7 months (3–134) in the etoposide arm (all patients in the Etoposide arm relapsed) (hazard ratio HR = 0.287, 95% CI: 0.076–0.884, p=0.03). Model forecast 10-yr overall survival rates as 64% in the Viscum arm and 33% in the etoposide arm. Lymphocyte subpopulation counts (CD3, CD4, and CD56) showed an increase in the Viscum arm while a decrease was observed in the etoposide arm during treatment. Conclusions. After 12 years from the start of the trial, the patients in the Viscum arm continue to show a considerably longer PRDFS compared to oral etoposide, and a trend for an advantage in OS is evident even if the number of treated patients is too small to draw conclusions. Viscum as maintenance treatment after complete surgical remission in relapsed osteosarcoma should be further investigated and compared with other drugs.

Sign in / Sign up

Export Citation Format

Share Document